What Is Seres Therapeutics, Inc. (MCRB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Seres Therapeutics, Inc.'s intrinsic value is estimated at a composite fair value of $9.52. While the stock appears modestly undervalued at $5.62 (implied upside of +69.4%), our analysis suggests a thinner margin of safety across 7 of 11 bullish models. Notably, Dynamic NAV sees the most upside at +274.1% (fair value: $21.03), while RCMH-DCF is the most conservative at -88.7% ($0.64). The spread between these extremes — +362.8% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About MCRB?
11 of 13 models are currently active for MCRB. Of these, 7 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates MCRB's intrinsic value at $6.84, implying +21.6% upside from the current price. See which stocks rank higher →
How Does MCRB Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, MCRB ranks #350 by Quality of Company score. CirclFi's QOC score of 3.9/10 evaluates 32 fundamental signals. A score of 3.9 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to healthcare company businesses. For Seres Therapeutics, Inc., metrics like R&D productivity ratio provide important context that general-purpose valuation models may underweight.
Is MCRB a Value Trap?
CirclFi's Value Trap algorithm assigns MCRB a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Seres Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Seres Therapeutics, Inc. scores 3.9 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +362.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every MCRB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across MCRB's 11 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad